Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company has authorized the issue and sale of $56,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.83% Senior Notes, Series 2013A, due July 1, 2020, (the “Series A Notes”), (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (the “Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”). The Series A Notes, the Series B Notes and the Series C Notes are herein collectively referred to as the “Notes.” As used herein, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and any such notes issued in substitution therefor pursuant to Section 14. The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms set out in Exhibit 1(a), Exhibit 1(b) and Exhibit 1(c), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) $56,000,000 25,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.836.90% Senior Notes, Series 2013AA, due July 1January 30, 2020, 2007 (the “Series A Notes”), (b) $12,000,000 28,000,000 aggregate principal amount of its 4.457.31% Senior Notes, Series 2013BB, due December 1January 30, 2022 2012 (the “Series B Notes”) ), and (c) $30,000,000 22,000,000 aggregate principal amount of its 4.847.85% Senior Notes, Series 2013CC, due October 1January 30, 2027 2012 (the “Series C Notes”). The ; the Series A Notes, the Series B Notes and the Series C Notes are herein being hereinafter collectively referred to as the “Notes.” As used herein”, the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1413 of this Agreement or the Other Agreements (as hereinafter defined)). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a), Exhibit 1(b) and Exhibit 1(c), respectively, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) $56,000,000 17,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.835.13% Senior Notes, Series 2013AA, due July 1December 16, 2020, 2016 (the “Series A Notes”), (b) $12,000,000 33,000,000 aggregate principal amount of its 4.455.13% Senior Notes, Series 2013BB, due December 1February 24, 2022 2017 (the “Series B Notes”) and ), (c) $30,000,000 35,000,000 aggregate principal amount of its 4.845.61% Senior Notes, Series 2013CC, due October 1December 16, 2027 2019 (the “Series C Notes”). The , and (d) $65,000,000 aggregate principal amount of its 5.61% Senior Notes, Series D, due February 24, 2020 (the “Series D Notes”; the Series A Notes, the Series B Notes, the Series C Notes and the Series C D Notes are herein being hereinafter collectively referred to as the “Notes.” As used herein”, the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1413). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a)1-A, Exhibit 1(b) and Exhibit 1(c)1-B, respectively1-C or 1-D, as the case may be. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) $56,000,000 65,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.835.28% Senior Notes, Series 2013AG, due July 1August 25, 2020, 2015 (the “"Series A G Notes”"), (b) $12,000,000 65,000,000 aggregate principal amount of its 4.455.38% Senior Notes, Series 2013BH, due December 1August 25, 2022 2017 (the “"Series B H Notes”") and (c) $30,000,000 20,000,000 aggregate principal amount of its 4.845.49% Senior Notes, Series 2013CI, due October 1August 25, 2027 2020 (the “"Series C I Notes”). The "; the Series A I Notes, the Series B H Notes and the Series C G Notes are herein being hereinafter collectively referred to as the “"Notes.” As used herein, the ," such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 14SECTION 13 of this Agreement or the Other Agreements (as hereinafter defined)). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(aEXHIBIT 1(A), Exhibit 1(bEXHIBIT 1(B) and Exhibit 1(cEXHIBIT 1(C), respectively, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule SCHEDULE B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. (a) The Company has authorized will authorize the issue and sale of (a) $56,000,000 25,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.833.77% Senior Notes, Series 2013AA, due July 1November 28, 2020, 2016 (the “Series A Notes”), (b) $12,000,000 25,000,000 aggregate principal amount of its 4.454.14% Senior Notes, Series 2013BB, due December 1November 28, 2022 2017 (the “Series B Notes”) ), and (c) $30,000,000 25,000,000 aggregate principal amount of its 4.844.47% Senior Notes, Series 2013CC, due October 1November 28, 2027 2018 (the “Series C Notes”). The Series A Notes, and together with the Series B Notes and the Series C Notes are herein collectively referred to as A Notes, the “Notes.,” As used herein, the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes Notes issued in substitution therefor pursuant to Section 1413 of this Agreement). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a), Exhibit 1(b) and Exhibit 1(c), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. (b) The Notes shall bear interest computed on the basis of a 360-day year of twelve 30-day months) on the unpaid principal amount thereof from the date of issuance, payable semiannually, on May 28 and November 28 in each year and on the maturity date of the Notes.

Authorization of Notes. The Company has authorized will authorize the issue and sale of $56,000,000 250,000,000 aggregate principal amount of its Series 2014-A Senior Notes consisting of (a) $14,000,000 125,000,000 aggregate principal amount of its 3.833.84% Series 2014-A Senior Notes, Series 2013ATranche 1, due July 1September 19, 2020, 2024 (the “Series 2014-A Tranche 1 Notes”), ) and (b) $12,000,000 125,000,000 aggregate principal amount of its 4.454.24% Series 2014-A Senior Notes, Series 2013BTranche 2, due December 1June 25, 2022 2025 (the “Series B 2014-A Tranche 2 Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, ; the Series 2013C, due October 1, 2027 (2014-A Tranche 2 Notes together with the Series 2014-A Tranche 1 Notes are collectively referred to herein as the “Series C 2014-A Notes”). The Series 2014-A Notes, Notes together with each Series of Additional Notes which may from time to time be issued pursuant to the Series B Notes and the Series C Notes provisions of Section 2.2 are herein collectively referred to herein as the “Notes.” As used herein, the (such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and also include any such notes issued in substitution therefor pursuant to Section 1413). The Series 2014-A Notes, the Series B Tranche 1 Notes and the Series C 2014-A Tranche 2 Notes shall be substantially in the forms set out in Exhibit 1(a), Exhibit 1(b) and Exhibit 1(c1(b), respectively, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) $56,000,000 18,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.833.15% Senior Guaranteed Notes, Series 2013AA, due July 1November 30, 2020, 2017 (the “Series A Notes”), ) and (b) $12,000,000 20,000,000 aggregate principal amount of its 4.453.61% Senior Guaranteed Notes, Series 2013BB, due December 1November 30, 2022 2019 (the “Series B Notes”) and ), (c) $30,000,000 117,000,000 aggregate principal amount of its 4.844.17% Senior Guaranteed Notes, Series 2013CC, due October 1November 30, 2027 2022 (the “Series C Notes”). The ) and (d) $20,000,000 aggregate principal amount of its 4.33% Senior Guaranteed Notes, Series D, due November 30, 2024 (the “Series D Notes”, and collectively with the Series A Notes, the Series B Notes and the Series C Notes are herein collectively referred to as Notes, the “Notes.” As used herein”, the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor therefore pursuant to Section 1413). Each series of Notes issued hereunder are sometimes referred to as Notes of a “Series.” The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a)Exhibits 1-A, Exhibit 1(b) 1-B, 1-C and Exhibit 1(c)1-D, respectivelyrespectively with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.. Mid-America Apartments, L.P. Note Purchase Agreement

Authorization of Notes. The Company has authorized will authorize the issue and sale of $56,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.837.19% Senior Notes, Series 2013AF, due July 1December 16, 2020, 2004 (the “"Series A F Notes”), (b") $12,000,000 in an aggregate principal amount of $10,000,000 and its 4.457.23% Senior Notes, Series 2013BG, due December 116, 2022 2005 (the “"Series B G Notes”") and (c) $30,000,000 in an aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 $10,000,000 (the “Series C Notes”). The Series A Notes, the Series B F Notes and the Series C G Notes are herein hereinafter collectively referred to as the “"Notes.” As used herein", the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1413 of this Agreement). The Series A Notes, the Series B F Notes and the Series C G Notes shall be substantially in the forms form set out in Exhibit 1(a), Exhibit 1(b) Exhibits 1 and Exhibit 1(c)2, respectively, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized Operating Partnership will authorize the issue and sale of (i) $44,000,000 aggregate principal amount of its 7.47% Series A Senior Notes due January 15, 2004 (the "Series A Notes") and (ii) $56,000,000 aggregate principal amount of its 7.66% Series B Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.83% Senior Notesdue January 15, Series 2013A, due July 1, 2020, 2007 (the “Series A Notes”), (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (the “"Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”"). The Series A Notes, Notes and the Series B Notes and the Series C Notes are herein hereinafter collectively referred to as the “"Notes.” As used herein", the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1413 of this Agreement or the Other Agreements (as hereinafter defined). The Series A Notes, Notes and the Series B Notes and the are each referred to as Notes of a "Series". The Series C A Notes shall be substantially in the forms form set out in Exhibit 1(a)1-A and the Series B Notes shall be substantially in the form set out in Exhibit 1-B, Exhibit 1(b) in each case, with such changes therefrom, if any, as may be approved by you and Exhibit 1(c), respectivelythe Operating Partnership. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (i) $56,000,000 18,000,000 aggregate principal amount of its 7.04% Senior Notes consisting of Secured Guaranteed Notes, Series A, due August 1, 2008 (athe "SERIES A NOTES") and (ii) $14,000,000 9,000,000 aggregate principal amount of its 3.837.14% Senior Secured Guaranteed Notes, Series 2013AB, due July August 1, 2020, 2010 (the “Series A Notes”)"SERIES B NOTES" and, (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (together with the “Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”). The Series A Notes, the Series B Notes and the Series C Notes are herein collectively referred "NOTES," such term to as the “Notes.” As used herein, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor for the appropriate series pursuant to Section 1413 of this Agreement or the Other Agreements (as hereinafter defined)). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a)1-A and the Series B Notes shall be substantially in the form of Exhibit 1-B, Exhibit 1(b) in each case, with such changes therefrom, if any, as may be approved by you and Exhibit 1(c), respectivelythe Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) $56,000,000 95,000,000 aggregate principal amount of its 5.20% Senior Notes consisting of Notes, Series A, due October 28, 2012 (athe "Series A Notes") and (b) $14,000,000 5,000,000 aggregate principal amount of its 3.835.88% Senior Notes, Series 2013AB, due July 1October 28, 2020, 2012 (the “Series A Notes”), (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (the “"Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 ("; the “Series C Notes”). The Series A Notes, Notes and the Series B Notes and the Series C Notes are herein being hereinafter collectively referred to as the “"2002 Notes.” As used herein"). The 2002 Notes, the term “Notes” shall mean all notes (irrespective together with each series of series unless otherwise specified) originally delivered Additional Notes which may from time to time be issued pursuant to this Agreement and the provisions of Section 2.2 are collectively referred to as the "Notes" (such term shall also include any such notes issued in substitution therefor pursuant to Section 1414 of this Agreement or the Other Agreements (as hereinafter defined)). The Series A Notes, the Series B Notes and the Series C B Notes shall be substantially in the forms form set out in Exhibit 1(a), Exhibit 1(b) Exhibits 1-A and Exhibit 1(c)1-B, respectively, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized the issue and sale of NFC will authorize: (i) $56,000,000 315,000,000 aggregate principal amount of its 5.21% Series A Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.83% Senior Notesdue November 28, Series 2013A, due July 1, 2020, 2012 (the “Series A Notes”), (bii) $12,000,000 230,000,000 aggregate principal amount of its 4.455.36% Series B Senior NotesNotes due November 28, Series 2013B, due December 1, 2022 2015 (the “Series B Notes”) and ), (ciii) $30,000,000 90,000,000 aggregate principal amount of its 4.845.41% Series C Senior NotesNotes due November 28, Series 2013C, due October 1, 2027 2016 (the “Series C Notes”). The , and (iv) $265,000,000 aggregate principal amount of its 5.89% Series D Senior Notes due November 28, 2025 (the “Series D Notes”; the Series A Notes, the Series B Notes, the Series C Notes and the Series C D Notes are herein collectively referred to herein as the “Notes.” As used herein”, the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1413 of this Agreement). The Series A Notes, the Series B Notes, Series C Notes and the Series C D Notes shall be substantially in the forms form set out in Exhibit 1(a), Exhibit 1(b) and ), Exhibit 1(c), and Exhibit 1(d), respectively. The Notes shall be fully and unconditionally guaranteed by the Company pursuant to Section 23 of this Agreement. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of $56,000,000 5,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.836.58% Senior Notes, Series 2013AA, due July 1August 10, 2020, 2008 (the “"Series A Notes”), (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (the “Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”). The Series A Notes, the Series B Notes and the Series C Notes are herein collectively referred ," such term to as the “Notes.” As used herein, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes of such series issued in substitution therefor pursuant to Section 1413 of this Agreement or the Other Agreements (as hereinafter defined)) and $25,000,000 aggregate principal amount of its 6.87% Senior Notes, Series B, due August 10, 2011 (the "Series B Notes," such term to include any such notes of such series issued in substitution therefor pursuant to Section 13 of this Agreement or the Other Agreements; the Series A Notes and Series B Notes are hereinafter collectively referred to as the "Notes"). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a)1-A, and the Series B Notes shall be substantially in the form set out in Exhibit 1(b) 1-B, in each case, with such changes therefrom, if any, as may be approved by you and Exhibit 1(c), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreementthe Company.

Authorization of Notes. The Company has authorized Issuer will authorize the issue and sale of $56,000,000 75,000,000 aggregate principal amount of its Senior Notes consisting of (ai) $14,000,000 25,000,000 aggregate principal amount of its 3.834.09% Senior Notes, Series 2013AA, due July 1August 11, 2020, 2025 (the “Series A Notes”), (bii) $12,000,000 25,000,000 aggregate principal amount of its 4.454.18% Senior Notes, Series 2013BB, due December 1August 11, 2022 2026 (the “Series B Notes”) and (ciii) $30,000,000 25,000,000 aggregate principal amount of its 4.844.24% Senior Notes, Series 2013CC, due October 1August 11, 2027 (the “Series C Notes”). The ” and, together with the Series A Notes and Series B Notes, the Series B Notes and the Series C Notes are herein collectively referred to as the “Notes.” As used herein”, the such term “to include any Notes” shall mean all notes (irrespective of series unless , as amended, restated or otherwise specified) originally delivered modified from time to time pursuant to this Agreement Section 17, and any such notes Notes issued in substitution therefor pursuant to Section 1413). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit Exhibits 1(a), Exhibit 1(b) and Exhibit 1(c), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references B. References to a “Schedule” or an “Exhibit” are, unless otherwise specified, are references to a Schedule or an Exhibit attached to this AgreementAgreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified. SECTION 2.

Authorization of Notes. The Company has authorized Obligors will authorize the issue and sale of $56,000,000 215,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.83their 5.99% Senior Notes, Series 2013A2006-A, due July 1February 27, 2020, 2016 (the “Series 2006-A Notes”), (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (the “Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”). The Series 2006-A Notes, together with each series of Additional Notes which may from time to time be issued pursuant to the Series B Notes and the Series C Notes provisions of Section 2.2, are herein collectively referred to as the “Notes.” As used herein, the (such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1413 of this Agreement or the Other Agreements (as hereinafter defined)). The Series 2006-A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a)1, Exhibit 1(b) with such changes therefrom, if any, as may be approved by you and Exhibit 1(c), respectivelythe Obligors. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. SECTION 2.

Authorization of Notes. The Company has authorized will authorize the issue and sale of $56,000,000 aggregate principal amount of its Senior Notes consisting of (a) $€14,000,000 aggregate principal amount of its 3.835.177% Senior Notes, Series 2013A2006-A, due July 1February 9, 2020, 2011 (the “Series A Notes”), ) and (b) $12,000,000 £3,000,000 aggregate principal amount of its 4.456.565% Senior Notes, Series 2013B2006-B, due December 1February 9, 2022 2011 (the “Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”). The Series A Notes, Notes and the Series B Notes and the Series C Notes are herein collectively referred to as the “Notes.” As used herein, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and any such notes issued in substitution therefor pursuant to Section 1413 of this Agreement. The Series A Notes, the Series B Notes and the Series C B Notes shall be substantially in the forms set out in Exhibit 1(a), Exhibit 1(b) and Exhibit 1(c1(b), respectively, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of $56,000,000 250,000,000 aggregate principal amount of its Senior Notes consisting Notes, of (a) which $14,000,000 95,000,000 aggregate principal amount of shall be its 3.834.23% Series A Senior NotesNotes due September 10, Series 2013A, due July 1, 2020, 2023 (the “Series A Notes”), (b) $12,000,000 80,000,000 aggregate principal amount of shall be its 4.454.47% Series B Senior NotesNotes due September 10, Series 2013B, due December 1, 2022 2025 (the “Series B Notes”) and (c) $30,000,000 75,000,000 aggregate principal amount of shall be its 4.844.57% Series C Senior Notes, Series 2013C, Notes due October 1September 10, 2027 (the “Series C Notes”). The ; the Series A Notes, the Series B Notes Notes, and the Series C Notes are herein collectively referred Notes, as amended, restated or otherwise modified from time to as the “Notes.” As used herein, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered time pursuant to this Agreement Section 17 and including any such notes issued in substitution therefor pursuant to Section 1413, the “Notes”). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the respective forms set out in Exhibit Schedules 1(a), Exhibit 1(b) and Exhibit 1(c), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references A. References to a “Schedule” or an “Exhibit” are, unless otherwise specified, are references to a Schedule or an Exhibit attached to this AgreementAgreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) $56,000,000 50,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.83% Floating Rate Series A Senior Notes, Series 2013A, due July 128, 2020, 2012 (the “Series A Notes”), (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (the “Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”). The Series A Notes, the Series B Notes and the Series C Notes are herein collectively referred such term to as the “Notes.” As used herein, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1413) and (b) $25,000,000 aggregate principal amount of its Floating Rate Series B Senior Notes, due July 28, 2015 (the “Series B Notes” such term to include any such notes issued in substitution therefor pursuant to Section 13, and together with the Series A Notes, collectively, the “Notes”). The Series A Notes, the Series B Notes and the Series C B Notes shall be substantially in the forms set out in Exhibit 1(a), Exhibit 1(b) and Exhibit 1(c1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized the issue and sale of (i) $56,000,000 150,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.833.51% Senior Notes, Series 2013AE, due July 1June 13, 20202025 (as amended, (the “Series A Notes”)supplemented, (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notesrestated or otherwise modified from time to time, Series 2013B, due December 1, 2022 (the “Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”). The Series A Notes, the Series B Notes and the Series C Notes are herein collectively referred to as the “Notes.” As used herein, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and including any such notes issued in substitution therefor pursuant to Section 1413 of this Agreement, the “Series E Notes”) and (ii) $250,000,000 aggregate principal amount of its 3.77% Senior Notes, Series F, due August 22, 2028 (as amended, supplemented, restated or otherwise modified from time to time, including any such notes issued in substitution therefor pursuant to Section 13 of this Agreement, the “Series F Notes” and, together with the Series E Notes, the “Notes”). The Series A Notes, the Series B E Notes and the Series C Notes shall will be substantially in the forms set out form of Exhibit 1(e) and the Series F Notes will be substantially in the form of Exhibit 1(a1(f), Exhibit 1(b) in each case with such changes therefrom, if any, as may be approved by you and Exhibit 1(c), respectivelythe Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of $56,000,000 300,000,000 aggregate principal amount of its Senior Notes senior notes consisting of (a) $14,000,000 150,000,000 aggregate principal amount of its 3.832.81% Series 2022-A Senior NotesNotes due March 17, Series 2013A, due July 1, 2020, 2037 (the “Series 2022-A Notes”), ) and (b) $12,000,000 150,000,000 aggregate principal amount of its 4.452.91% Series 2022-B Senior Notes, Series 2013B, Notes due December September 1, 2022 2037 (the “Series 2022-B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”). The Series 2022-A Notes, the Series B Notes and the Series C Notes are herein collectively referred 2022-B Notes, as amended, restated or otherwise modified from time to as the “Notes.” As used herein, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered time pursuant to this Agreement Section 17 and including any such notes issued in substitution therefor pursuant to Section 1413, each a “Note” and collectively, the “Notes”. The Series 2022-A Notes, the Series B Notes and the Series C 2022-B Notes shall be substantially in the forms set out in Exhibit Exhibits 1(a), Exhibit 1(b) and Exhibit 1(c1(b), respectively, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) Cdn. $56,000,000 30,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.834.34% Senior Notes, Series 2013AA, due July 1May 15, 2020, 2019 (the “Series A Notes”), (b) U.S. $12,000,000 20,000,000 aggregate principal amount of its 4.454.40% Senior Notes, Series 2013BB, due December 1May 15, 2022 (the “Series B Notes”) and (c) U.S. $30,000,000 355,000,000 aggregate principal amount of its 4.844.40% Senior Notes, Series 2013CC, due October 1May 15, 2027 2024 (the “Series C Notes”). The , together with the Series A Notes and Series B Notes, the Series B Notes and the Series C Notes are herein collectively referred to as the “Notes.” As used herein”), the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes Notes issued in substitution therefor pursuant to Section 1414 of this Agreement or the Other Agreements (as hereinafter defined)). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a)1-A, Exhibit 1(b) 1-B and Exhibit 1(c)1-C, respectivelywith such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Section,” “Schedule” or an “Exhibit” are, unless otherwise specified, to a Section of, or a Schedule or an Exhibit attached to to, this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) $56,000,000 50,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.834.68% Senior Guaranteed Notes, Series 2013AA, due July 129, 2020, 2018 (the “Series A Notes”), (b) $12,000,000 72,750,000 aggregate principal amount of its 4.455.40% Senior Guaranteed Notes, Series 2013BB, due December 1July 29, 2022 2021 (the “Series B Notes”) and (c) $30,000,000 12,250,000 aggregate principal amount of its 4.845.57% Senior Guaranteed Notes, Series 2013CC, due October 1July 29, 2027 2023 (the “Series C Notes”). The , and collectively with the Series A Notes, the Series B Notes and the Series C Notes are herein collectively referred to as B Notes, the “Notes.” As used herein”, the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor therefore pursuant to Section 1413). Each series of Notes issued hereunder are sometimes referred to as Notes of a “Series.” The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a)Exhibits 1-A, Exhibit 1(b) 1-B and Exhibit 1(c)1-C, respectivelyrespectively with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of $56,000,000 its senior notes, of which (a) €135,000,000 aggregate principal amount of shall be its 1.30% Series 2019-B Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.83% Senior Notesdue November 6, Series 2013A, due July 1, 2020, 2034 (the “Series A Notes”), (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (the “Series 2019-B Notes”) and (cb) $30,000,000 50,000,000 aggregate principal amount of shall be its 4.843.19% Series 2019-C Senior NotesNotes due January 24, Series 2013C, due October 1, 2027 2035 (the “Series 2019-C Notes”). The ; together with the Series A 2019-B Notes, in each case as may be amended, restated or otherwise modified from time to time pursuant to the Series B Notes and the Series C Notes are herein provisions of Section 17, collectively referred to as the “Notes.” As used herein, the (such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and also include any such notes issued in substitution therefor pursuant to Section 1413)). The Series A Notes, the Series 2019-B Notes and the Series 2019-C Notes shall be substantially in the forms set out in Exhibit Exhibits 1(a), Exhibit 1(b) and Exhibit 1(c1(b), respectively, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) U.S. $56,000,000 85,500,000 aggregate principal amount of its 7.84% Senior Notes consisting of Guaranteed Notes, Series A, due March 25, 2006 (athe "Series A Notes") and (b) U.S. $14,000,000 114,500,000 aggregate principal amount of its 3.838.05% Senior Guaranteed Notes, Series 2013AB, due July 1March 25, 2020, 2009 (the “Series A Notes”), (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (the “"Series B Notes”) "; the Series A Notes and (c) $30,000,000 aggregate principal amount of its 4.84% Senior the Series B Notes are hereinafter referred to collectively as the "Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”"). The References herein to the Series A Notes, the Series B Notes and or the Series C Notes are herein collectively referred to as the “Notes.” As used hereinshall, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 14SECTION 13 or the Other Agreements (as hereinafter defined)). The Series A Notes, the Series B Notes and the Series C B Notes shall be substantially in the forms set out in Exhibit 1(a), Exhibit 1(b) and Exhibit 1(c)EXHIBIT 1-A AND 1-B, respectively, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule SCHEDULE B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement."SECTION"

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) $56,000,000 125,000,000 aggregate principal amount of its 10% Series A-2009 Senior Notes consisting of due February 13, 2017 (a) $14,000,000 aggregate principal amount of its 3.83% Senior Notesas amended, Series 2013Arestated or otherwise modified from time to time, due July 1, 2020, (the “Series A Notes”), (b) $12,000,000 aggregate principal amount of its 4.45% Senior Notes, Series 2013B, due December 1, 2022 (the “Series B Notes”) and (c) $30,000,000 aggregate principal amount of its 4.84% Senior Notes, Series 2013C, due October 1, 2027 (the “Series C Notes”). The Series A Notes, the Series B Notes and the Series C Notes are herein collectively referred to as the “Notes.” As used herein, the term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and together with any such notes issued in substitution therefor pursuant to Section 14. The 13, the "Series A Notes") and (b) $125,000,000 aggregate principal amount of its 10% Series B-2009 Senior Notes due February 13, 2019 (as amended, restated or otherwise modified from time to time, together with any such notes issued in substitution therefor pursuant to Section 13, the "Series B Notes", and together with the Series A Notes, the "Notes"). The Series B A Notes and the Series C B Notes shall be substantially in the forms form set out in Exhibit 1(a), Exhibit 1(b) 1A and Exhibit 1(c)1B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement; and references to a "Section" are, unless otherwise specified, references to a Section of this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) U.S. $56,000,000 40,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.836.82% Senior Notes, Series 2013AA, due July 1June 18, 2020, 2015 (the “Series A Notes”), (b) Cdn. $12,000,000 40,000,000 aggregate principal amount of its 4.456.37% Senior Notes, Series 2013BB, due December 1June 18, 2022 2015 (the “Series B Notes”) and (c) U.S. $30,000,000 225,000,000 aggregate principal amount of its 4.847.97% Senior Notes, Series 2013CC, due October 1June 18, 2027 2021 (the “Series C Notes”). The ; the Series A Notes, the Series B Notes and the Series C Notes are herein being hereinafter collectively referred as to as the “Notes.” As used herein”, the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1414 of this Agreement or the Other Agreements (as hereinafter defined)). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a)1, Exhibit 1(b) 2 or Exhibit 3, as applicable with such changes therefrom, if any, as may be approved by you and Exhibit 1(c), respectivelythe Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Section,” “Schedule” or an “Exhibit” are, unless otherwise specified, to a Section of, or a Schedule or an Exhibit attached to to, this Agreement.

Authorization of Notes. The Company has authorized the issue and sale of (a) $56,000,000 197,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.836.33% Senior Notes, Series 2013AA, due July 115, 2020, 2014 (the “Series A Notes”), (b) $12,000,000 85,000,000 aggregate principal amount of its 4.456.52% Senior Notes, Series 2013BB, due December 1July 15, 2022 2017 (the “Series B Notes”) and (c) $30,000,000 93,000,000 aggregate principal amount of its 4.846.67% Senior Notes, Series 2013CC, due October 1July 15, 2027 2019 (the “Series C Notes”). The ,” and together with the Series A Notes, the Series B Notes and the Series C Notes B Notes, are herein collectively referred to as the “Notes.” As used herein”, the such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1413 of this Agreement). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms form set out in Exhibit 1(a)1-A, Exhibit 1(b) 1-B and Exhibit 1(c)1-C, respectively, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (i) $56,000,000 175,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.833.97% Senior Notes, Series 2013AA, due July 1August 27, 2020, 2023 (the “Series A Notes”), (bii) $12,000,000 150,000,000 aggregate principal amount of its 4.454.26% Senior Notes, Series 2013BB, due December 1August 27, 2022 2028 (the “Series B Notes”) and (ciii) $30,000,000 175,000,000 aggregate principal amount of its 4.844.60% Senior Notes, Series 2013CC, due October 1August 27, 2027 2033 (the “Series C Notes”). The ” and, together with the Series A Notes, the Series B Notes and the Series C Notes are herein collectively referred to as B Notes, the “Notes.” As used herein”), the term “Notes” shall mean all notes (irrespective of series unless in each case as amended, restated or otherwise specified) originally delivered modified from time to time pursuant to this Agreement Section 17 and including any such notes issued in substitution therefor pursuant to Section 1413. The Series A Notes, Notes shall be substantially in the form set out in Schedule 1(a). The Series B Notes and shall be substantially in the form set out in Schedule 1(b). The Series C Notes shall be substantially in the forms form set out in Exhibit 1(a), Exhibit 1(b) and Exhibit Schedule 1(c), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references A. References to a “Schedule” or an “Exhibit” are, are references to a Schedule attached to this Agreement unless otherwise specified, . References to a Schedule or an Exhibit attached “Section” are references to a Section of this AgreementAgreement unless otherwise specified.

Authorization of Notes. The Company has authorized will authorize the issue and sale of (a) $56,000,000 250,000,000 aggregate principal amount of its Senior Notes consisting of (a) $14,000,000 aggregate principal amount of its 3.834.49% Guaranteed Senior Notes, Series 2013AA, due July 1October 15, 20202022 (as amended, (restated, supplemented or otherwise modified from time to time, the “Series A Notes”), (b) $12,000,000 500,000,000 aggregate principal amount of its 4.454.93% Guaranteed Senior Notes, Series 2013BB, due December 1October 15, 2022 2025 (as amended, restated, supplemented or otherwise modified from time to time, the “Series B Notes”) and ), (c) $30,000,000 250,000,000 aggregate principal amount of its 4.845.03% Guaranteed Senior Notes, Series 2013CC, due October 115, 2027 (as amended, restated, supplemented or otherwise modified from time to time, the “Series C Notes”). The ; the Series A Notes, the Series B Notes and the Series C Notes are herein hereinafter collectively referred to as the “Notes.,” As used herein, the and each individually as a “Note,” such term “Notes” shall mean all notes (irrespective of series unless otherwise specified) originally delivered pursuant to this Agreement and include any such notes issued in substitution therefor pursuant to Section 1413). The Series A Notes, the Series B Notes and the Series C Notes shall be substantially in the forms set out in Exhibit 1(a)Schedule 1-A, Exhibit 1(b) Schedule 1-B, and Exhibit 1(c)Schedule 1-C, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.A.